GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Median Technologies (XPAR:ALMDT) » Definitions » EV-to-EBIT

Median Technologies (XPAR:ALMDT) EV-to-EBIT : -4.46 (As of Jan. 18, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Median Technologies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Median Technologies's Enterprise Value is €101.06 Mil. Median Technologies's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €-22.67 Mil. Therefore, Median Technologies's EV-to-EBIT for today is -4.46.

The historical rank and industry rank for Median Technologies's EV-to-EBIT or its related term are showing as below:

XPAR:ALMDT' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.76   Med: -7.93   Max: 0.86
Current: -4.46

During the past 13 years, the highest EV-to-EBIT of Median Technologies was 0.86. The lowest was -29.76. And the median was -7.93.

XPAR:ALMDT's EV-to-EBIT is ranked worse than
100% of 445 companies
in the Medical Devices & Instruments industry
Industry Median: 19.59 vs XPAR:ALMDT: -4.46

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Median Technologies's Enterprise Value for the quarter that ended in Jun. 2024 was €61.28 Mil. Median Technologies's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €-22.67 Mil. Median Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -36.99%.


Median Technologies EV-to-EBIT Historical Data

The historical data trend for Median Technologies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Median Technologies EV-to-EBIT Chart

Median Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.04 -6.97 -12.39 -7.41 -4.17

Median Technologies Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -7.41 - -4.17 -

Competitive Comparison of Median Technologies's EV-to-EBIT

For the Medical Devices subindustry, Median Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Median Technologies's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Median Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Median Technologies's EV-to-EBIT falls into.



Median Technologies EV-to-EBIT Calculation

Median Technologies's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=101.063/-22.67
=-4.46

Median Technologies's current Enterprise Value is €101.06 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Median Technologies's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €-22.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Median Technologies  (XPAR:ALMDT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Median Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=-22.67/61.2786545
=-36.99 %

Median Technologies's Enterprise Value for the quarter that ended in Jun. 2024 was €61.28 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Median Technologies's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €-22.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Median Technologies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Median Technologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Median Technologies Business Description

Traded in Other Exchanges
Address
1800 Route Des Cretes, Les Deux Arcs B, Valbonne, FRA, 06560
Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The firm intends to target the oncology clinical trials market and the cancer patient care market. It developed software-based tools that are integrated into a clinical application portfolio called Lesion Management Solutions. The company has two platforms, iSee for imaging services in clinical trials and iBiopsy for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer and other chronic diseases. Its geographical segments are France, the USA/Canada, the United Kingdom, China, and Other countries.

Median Technologies Headlines

No Headlines